King Rachel K. has filed 18 insider transactions across 3 companies since June 2023.
Most recent transaction: a grant/award of 36000 shares of Fulcrum Therapeutics, Inc. ($FULC) on June 26, 2025.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 26, 2025 | Fulcrum Therapeutics, Inc. | $FULC | King Rachel K. | Not found | A | Stock Option (right to buy) | 36000 | $0.00 | 36,000.0000 | 61,984 | 9999.99% | 58.08% |
| June 20, 2025 | NOVAVAX INC | $NVAX | King Rachel K. | Director | A | Stock Option (Right to Buy) | 28326 | $6.42 | 28,326.0000 | 152,190,000 | 9999.99% | 0.02% |
| June 20, 2025 | NOVAVAX INC | $NVAX | King Rachel K. | Director | A | Restricted Stock Units | 18884 | $0.00 | 18,884.0000 | 152,190,000 | 9999.99% | 0.01% |
| June 12, 2025 | NOVAVAX INC | $NVAX | King Rachel K. | Not found | M | Common Stock | 10420 | $0.00 | 25,190.0000 | 152,190,000 | 70.55% | 0.01% |
| June 12, 2025 | NOVAVAX INC | $NVAX | King Rachel K. | Not found | M | Restricted Stock Units | 10420 | $0.00 | 0.0000 | 152,190,000 | 100.00% | 0.01% |
| Dec. 13, 2024 | NOVAVAX INC | $NVAX | King Rachel K. | Not found | S | Common Stock | 4150 | $9.02 | 14,770.0000 | 160,049,000 | 21.93% | 0.00% |
| Nov. 12, 2024 | Fulcrum Therapeutics, Inc. | $FULC | King Rachel K. | Not found | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 63,688,000 | 9999.99% | 0.09% |
| June 12, 2024 | NOVAVAX INC | $NVAX | King Rachel K. | Not found | A | Stock Option (Right to Buy) | 15630 | $15.86 | 15,630.0000 | 100,768,000 | 9999.99% | 0.02% |
| June 12, 2024 | NOVAVAX INC | $NVAX | King Rachel K. | Not found | A | Restricted Stock Units | 10420 | $0.00 | 10,420.0000 | 100,768,000 | 9999.99% | 0.01% |
| June 12, 2024 | NOVAVAX INC | $NVAX | King Rachel K. | Not found | M | Restricted Stock Units | 6670 | $0.00 | 0.0000 | 100,768,000 | 100.00% | 0.01% |
| June 12, 2024 | NOVAVAX INC | $NVAX | King Rachel K. | Not found | M | Common Stock | 6670 | $0.00 | 18,920.0000 | 100,768,000 | 54.45% | 0.01% |
| May 1, 2024 | CRESCENT BIOPHARMA, INC. | $CBIO | King Rachel K. | Not found | A | Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| March 29, 2024 | CRESCENT BIOPHARMA, INC. | $CBIO | King Rachel K. | Not found | A | Common Stock | 3334 | $3.00 | 659,095.0000 | 0 | 0.51% | 0.00% |
| Dec. 29, 2023 | CRESCENT BIOPHARMA, INC. | $CBIO | King Rachel K. | Director | A | Common stock | 4238 | $2.36 | 519,360.0000 | 0 | 0.82% | 0.00% |
| June 10, 2023 | NOVAVAX INC | $NVAX | King Rachel K. | Director | M | Common Stock | 3100 | $0.00 | 12,250.0000 | 78,183,000 | 33.88% | 0.00% |
| June 10, 2023 | NOVAVAX INC | $NVAX | King Rachel K. | Director | M | Restricted Stock Units | 3100 | $0.00 | 0.0000 | 78,183,000 | 100.00% | 0.00% |
| June 12, 2023 | NOVAVAX INC | $NVAX | King Rachel K. | Director | A | Stock Option (Right to Buy) | 7710 | $0.00 | 7,710.0000 | 78,183,000 | 9999.99% | 0.01% |
| June 12, 2023 | NOVAVAX INC | $NVAX | King Rachel K. | Director | A | Restricted Stock Units | 6670 | $0.00 | 6,670.0000 | 78,183,000 | 9999.99% | 0.01% |